1. Home
  2. RDNW vs GLSI Comparison

RDNW vs GLSI Comparison

Compare RDNW & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RideNow Group Inc.

RDNW

RideNow Group Inc.

HOLD

Current Price

$4.93

Market Cap

227.8M

Sector

Technology

ML Signal

HOLD

Logo Greenwich LifeSciences Inc.

GLSI

Greenwich LifeSciences Inc.

SELL

Current Price

$15.81

Market Cap

254.7M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
RDNW
GLSI
Founded
2013
2006
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
227.8M
254.7M
IPO Year
2014
2020

Fundamental Metrics

Financial Performance
Metric
RDNW
GLSI
Price
$4.93
$15.81
Analyst Decision
Hold
Strong Buy
Analyst Count
2
2
Target Price
$8.50
★ $57.00
AVG Volume (30 Days)
61.8K
★ 131.6K
Earning Date
11-03-2026
11-13-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 37.84
N/A
EPS
★ 0.06
N/A
Revenue
★ $1,793,369,000.00
N/A
Revenue This Year
$3.88
N/A
Revenue Next Year
$5.55
N/A
P/E Ratio
$80.17
★ N/A
Revenue Growth
★ 91.10
N/A
52 Week Low
$3.20
$7.78
52 Week High
$8.55
$34.10

Technical Indicators

Market Signals
Indicator
RDNW
GLSI
Relative Strength Index (RSI) 35.33 43.70
Support Level $4.60 $14.57
Resistance Level $7.14 $19.97
Average True Range (ATR) 0.37 1.50
MACD -0.06 -0.22
Stochastic Oscillator 15.49 27.43

Price Performance

Historical Comparison
RDNW
GLSI

About RDNW RideNow Group Inc.

RideNow Group Inc operates solely as a powersports dealership group. Its offerings include new and pre-owned vehicles such as motorcycles, all-terrain vehicles (ATVs), side-by-side vehicles (SXS), and personal watercraft (PWC). It also sells parts, apparel, and accessories, and provides financing, insurance, and aftermarket products, along with repair and maintenance services. The majority of the company's revenue is derived from powersports vehicle sales, and the rest from parts, service and accessories/merchandise, and finance and insurance products.

About GLSI Greenwich LifeSciences Inc.

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Share on Social Networks: